Lernia VD, Bianchi L, Guerriero C, et al. - In a real-life cohort of 54 children and/or adolescents with severe plaque psoriasis, researchers determined drug efficacy and safety of the tumor necrosis factor-alpha blocker monoclonal antibody adalimumab. In this research, retrospective, multicenter analysis over a 52-week period is discussed. In this cohort of children with severe plaque psoriasis, adalimumab was effective and safe in a 52-week observation. There was no difference in efficacy between biologic-naïve and non-naïve individuals. The drug was well tolerated and there were no serious infections.